Evolus, Inc. Overview
Pro stress-test →Evolus is a performance beauty company delivering aesthetic products in the cash-pay market, with flagship product Jeuveau, a proprietary botulinum toxin formulation for reducing frown lines, and Evolysse, a collection of injectable hyaluronic acid gels. Jeuveau has rapidly achieved approximately 12% U.S. neurotoxin market share by Q3 2024.
Strategic Profile
Pro stress-test →Unlike diversified competitors, Evolus concentrates exclusively on high-growth aesthetics neurotoxin and filler markets, enabling tailored marketing and deeper relationships within the aesthetic community. The company has evolved the medical aesthetics business model by moving away from a reimbursement model and partnering with customers differently to provide greater value.
Competitive Landscape
Pro stress-test →Evolus competes in the high-growth aesthetics neurotoxin and filler markets against larger diversified players with therapeutic portfolios. The company differentiates through focused expertise, proprietary formulations, and digital-first marketing targeting practitioners and younger demographics.
Industry Context
Evolus, Inc. operates in Medical Aesthetics / Performance Beauty.
Key facts
Founded: 2012 · Headquarters: Newport Beach, US · Revenue: $0.27B · Market cap: $0.7B